{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030972","form_type":"8-K","ticker":"NXGL","cik":"0001468929","company_name":"NEXGEL, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.760274+00:00","generated_at":"2026-06-22T03:21:27.373360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NEXGEL Q3 revenue up 69.6% to $568k; gross margin improves to 26%","bullets":["Revenue $568k, +69.6% YoY; growth driven by branded consumer products.","Gross profit margin 26%, improved from negative margin in prior year; anticipates continued expansion.","Operating expenses $1.2M include $220k one-time franchise tax; R&D spending increased to $193k from $0.","Cash and marketable securities $7.4M; expects runway through 2024 to support R&D growth.","Positive results from proof-of-concept study for diclofenac hydrogel pain patches; new proprietary amblyopia eye patch developed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030972","json":"https://secwatch.observer/filing/0001493152-22-030972.json","markdown":"https://secwatch.observer/filing/0001493152-22-030972.md","text":"https://secwatch.observer/filing/0001493152-22-030972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/0001493152-22-030972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:21:27.373360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bde4991690e763bad2d02422940a8e6f6db6fd3","claim":"NEXGEL, INC. reported third quarter ended September 30, 2022 results: revenue $568 thousand.","evidence_excerpt":"demonstrated significant scar improvement in patients treated with SilverSeal. Third Quarter 2022 Financial Highlights Revenue for the three months ended September 30, 2022 was $568 thousand, an increase of 69.6%, when compared to $233 thousand for the three months ended September 30, 2021. The increase in overall revenue was due to sales growth in branded consumer","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/0001493152-22-030972-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$568 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}